Clinical Trial Update: Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED) [Phase 2]

View source ↗

Summary

This Phase 2 study evaluating HIV vaccine V520-027 was terminated; Merck posted results in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• V520

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Phase 2 | Status: TERMINATED | Results posted: 2010-11-04